Anticancer agent 310
Anticancer agent 310 is an antitumor agent. Anticancer agent 310 releases nitric oxide to induce mitochondrial ROS burst, triggers mitochondrial dysfunction and activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 apoptotic pathway. Anticancer agent 310 also reduces the levels of SHMT2 and MTHFD2, decreases the ratios of NADPH/NADP+ and GSH/GSSG, thereby disrupting redox homeostasis and exacerbating intracellular ROS accumulation. Anticancer agent 310 can be used in research related to gastric cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C33H36N2O12S
- Peso molecular:684.71
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Caspase
More
Actividad biológica
Descripciòn
In Vitro
Anticancer agent 310 (compound A9) (0.016-10 μM; 72 h) potently inhibits the proliferation of various human and murine tumor cell lines in vitro[1].
Anticancer agent 310 (1.6-40 nM; 12-14 days) inhibits the long-term colony-forming ability of HGC27 and AGS gastric cancer cells in a concentration-dependent manner[1].
Anticancer agent 310 (50-100 μM; 2 h) releases nitric oxide in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (2 μM; 12 h) induces mitochondrial ROS burst in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (2 μM) induces mitochondrial membrane potential depolarization in HGC27 and AGS gastric cancer cells, and this effect is reversed by ROS scavenging[1].
Anticancer agent 310 (2 μM; 36 h) induces apoptosis in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (0.5-2 μM; 24 h) activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 mitochondrial apoptotic pathway in HGC27 and AGS gastric cancer cells in a dose-dependent manner in vitro[1].
Anticancer agent 310 (0.5-2 μM; 24 h) downregulates SHMT2 and MTHFD2, key enzymes in the folate one-carbon metabolic pathway, in HGC27 and AGS gastric cancer cells in a dose-dependent manner by inhibiting the transcription factor ATF4[1].
Anticancer agent 310 (2 μM; 12 h) disrupts redox homeostasis in HGC27 and AGS gastric cancer cells and reduces the ratios of NADPH/NADP+ and GSH/GSSG[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7, HepG2, HCT-116, HGC27, U251, AGS, ES-2, A2780, K562, MEG01, CT26
-
Concentration:0.016, 0.08, 0.4, 2, 5, 10 μM
-
Incubation Time:72 h
-
Result:Exhibited sub-micromolar inhibitory activity across all tested cell lines, with IC50 values as follows: MCF-7: 0.19 μM; HepG2: 0.21 μM; HCT-116: 0.22 μM; HGC27: 0.10 μM; U251: 0.14 μM; AGS: 0.02 μM; ES-2: 0.12 μM; A2780: 0.11 μM; K562: 0.12 μM; MEG01: 0.40 μM; CT26: 0.26 μM.
-
Cell Line:HGC27, AGS
-
Concentration:2 μM
-
Incubation Time:36 h
-
Result:Increased total apoptotic cells in HGC27 cells from 10.99% (control) to 83.1%.
Induced a total apoptotic rate of 60.9% in AGS cells.
-
Cell Line:HGC27, AGS
-
Concentration:0.5, 1, 2 μM
-
Incubation Time:24 h
-
Result:Upregulated the expression of cytoplasmic cytochrome c, Bax, Cleaved Caspase-9, and Cleaved Caspase-3, and downregulated the expression of mitochondrial cytochrome c and Bcl-2 in a dose-dependent manner in both HGC27 and AGS cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCG mice treated HGC27 tumor fragments[1]
-
Dosage:5 mg/kg; 10 mg/kg; 15 mg/kg
-
Administration:intratumoral; daily; 14 days
-
Result:Reduced tumor weight relative to control at 5 mg/kg dose.
Achieved 95.3% tumor growth inhibition (TGI), with 4 out of 6 mice showing complete tumor regression at 10 mg/kg dose.
Achieved 98.78% TGI, with 5 out of 6 mice showing complete tumor regression at 15 mg/kg dose.
Decreased expression of Ki67, SHMT2, and MTHFD2 in tumor tissues relative to control group at 10 mg/kg and 15 mg/kg doses.
Caused no obvious body weight loss or mortality in any dose group.
Chemical Information
-
Peso molecular 684.71
-
Fòrmula C33H36N2O12S
-
SMILES
O=C1OCC2=C1CC[C@@]3(C)[C@@]2([H])C[C@H]4[C@]5(O4)[C@@]36[C@@H](O6)[C@H](O7)[C@@]7(C(O)(C)C)[C@H]5OC(CCCCOC8=NON=C8S(=O)(C9=CC=CC=C9)=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 310 Related Classifications
HY-182284 Related Classifications
Powered by Bioz
Keywords
- Anticancer agent 310
- Anticancer agent310
- Anticancer agent-310
- Reactive Oxygen Species (ROS)
- Apoptosis
- Bcl-2 Family
- Caspase
- SHMT
- Methylenetetrahydrofolate Dehydrogenase (MTHFD)
- Cytochrome P450
- GSH/GSSG
- xenograft mouse models
- SHMT2
- Bax/Bcl-2
- Cyt c
- Caspase-9
- Caspase-3
- apoptotic pathway
- MTHFD2
- folate one-carbon metabolism
- AGS cells
- gastric cancer cells
- redox homeostasis
- NADPH/NADP+
- Inhibitor
- inhibitor
- inhibit